Cure My Disease

Don't miss your cure!

 Log in / Sign up

New radiation approach aims to tame sarcoma with fewer sessions

NCT ID NCT03972930

Ongoing Disease control Sponsor: University of Wisconsin, Madison Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 02, 2026 · Updated 1 time

Summary

This phase 2 trial is testing a shorter course of high-dose radiation (hypofractionated radiotherapy) for soft tissue sarcoma. The goal is to see if this approach can control the tumor for at least two years while reducing damage to nearby healthy tissue. About 48 adults with inoperable or metastatic sarcoma will receive the treatment and be followed for up to five years.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Hypofractionated radiotherapy (high-dose radiation given in fewer sessions)
What this could lead to
If successful, this could offer a more convenient and potentially safer radiation option for people with soft tissue sarcoma, improving local tumor control.
What could go wrong
This is a small, early-phase trial (48 participants) with no control group, so results may not apply broadly. The approach may still cause side effects or fail to control the tumor long-term.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SOFT TISSUE SARCOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

sarcoma soft tissue sarcoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SOFT TISSUE SARCOMA

Contacts and locations

Locations

  • University of Wisconsin

    Madison, Wisconsin, 53705, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.